Recruiting IBI343 in Combination Therapy for Advanced Malignant Solid Tumors NCT07483554 Conditions CLDN18.2 Positive, Gastric/Gastroesophageal Junction Adenocarcinoma, Pancreatic Ductal Adenocarcinoma Locations The First Affiliated Hospital of Zhejiang University School of Medicine — Hangzhou, Zhejiang, China View Trial Details
Recruiting IBI343 in Combination With Sintilimab and SOX Regimen for Perioperative Treatment of Resectable, Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma NCT07483567 Conditions CLDN18.2 Positive, Gastroesophageal Junction Adenocarcinoma, Primary Gastric Adenocarcinoma Locations Beijing Cancer Hospital — Beijing, Beijing Municipality, China View Trial Details
